Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns

Cancer treatment has entered the era of precision medicine, where knowledge of a patient's genetic profile is used to facilitate early diagnosis, drug selection, prognosis, prediction of drug responsiveness, the onset of secondary resistance, and relapse. Circulating free DNA (cfDNA) has emerge...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jun-Liang Lu, Zhi-Yong Liang
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2016
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/f443e279774f4ecf8cda2b1b13aa8425
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f443e279774f4ecf8cda2b1b13aa8425
record_format	dspace
spelling	oai:doaj.org-article:f443e279774f4ecf8cda2b1b13aa84252021-12-02T11:50:04ZCirculating free DNA in the era of precision oncology: Pre- and post-analytical concerns2095-882X10.1016/j.cdtm.2016.12.001https://doaj.org/article/f443e279774f4ecf8cda2b1b13aa84252016-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X16300810https://doaj.org/toc/2095-882XCancer treatment has entered the era of precision medicine, where knowledge of a patient's genetic profile is used to facilitate early diagnosis, drug selection, prognosis, prediction of drug responsiveness, the onset of secondary resistance, and relapse. Circulating free DNA (cfDNA) has emerged as an ideal source of genetic information for cancer patients, and numerous studies have explored its validity in various clinical applications. However, clinical implementation of cfDNA-based tests has been slow. In this review, we addressed some of the pre- and post-analytical issues regarding cfDNA tests. First, we summarized the characteristics of cfDNA and reviewed the methods used to identify tumor-derived cfDNA from the pool of total cfDNA. Second, we described the procedures used to extract cfDNA, which have a great impact on representativeness and yield. Finally, we discussed our thoughts on the validation of cfDNA-based tests and the reporting of test results amid drastic limitations. Keywords: Circulating free DNA, Characterization, Extraction, Validation, InterpretationJun-Liang LuZhi-Yong LiangKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 2, Iss 4, Pp 223-230 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Jun-Liang Lu Zhi-Yong Liang Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns
description	Cancer treatment has entered the era of precision medicine, where knowledge of a patient's genetic profile is used to facilitate early diagnosis, drug selection, prognosis, prediction of drug responsiveness, the onset of secondary resistance, and relapse. Circulating free DNA (cfDNA) has emerged as an ideal source of genetic information for cancer patients, and numerous studies have explored its validity in various clinical applications. However, clinical implementation of cfDNA-based tests has been slow. In this review, we addressed some of the pre- and post-analytical issues regarding cfDNA tests. First, we summarized the characteristics of cfDNA and reviewed the methods used to identify tumor-derived cfDNA from the pool of total cfDNA. Second, we described the procedures used to extract cfDNA, which have a great impact on representativeness and yield. Finally, we discussed our thoughts on the validation of cfDNA-based tests and the reporting of test results amid drastic limitations. Keywords: Circulating free DNA, Characterization, Extraction, Validation, Interpretation
format	article
author	Jun-Liang Lu Zhi-Yong Liang
author_facet	Jun-Liang Lu Zhi-Yong Liang
author_sort	Jun-Liang Lu
title	Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns
title_short	Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns
title_full	Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns
title_fullStr	Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns
title_full_unstemmed	Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns
title_sort	circulating free dna in the era of precision oncology: pre- and post-analytical concerns
publisher	KeAi Communications Co., Ltd.
publishDate	2016
url	https://doaj.org/article/f443e279774f4ecf8cda2b1b13aa8425
work_keys_str_mv	AT junlianglu circulatingfreednaintheeraofprecisiononcologypreandpostanalyticalconcerns AT zhiyongliang circulatingfreednaintheeraofprecisiononcologypreandpostanalyticalconcerns
_version_	1718395200840138752

Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns

Ejemplares similares